Stock Earnings GLUE stock rated an Equal weight by Wells Fargo Monte Rosa Therapeutics Inc’s filing revealed that its Principal Accounting Officer Dunn Edmund unloaded Company’s shares for reported $9174.0 on
Insiders Updates Understanding the Risks of Investing in Monte Rosa Therapeutics Inc (GLUE) In a filing, Monte Rosa Therapeutics Inc revealed its Principal Accounting Officer Dunn Edmund unloaded Company’s shares for reported $9174.0
Stock Earnings Negative sentiment towards GLUE reflected by a jump of 5.37% in short interest Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Monte Rosa
Analysts Viewpoint An Analysis of Monte Rosa Therapeutics Inc (GLUE)’s Potential Price Growth In a filing, Monte Rosa Therapeutics Inc revealed its Principal Accounting Officer Dunn Edmund unloaded Company’s shares for reported $9174.0